Comparing a Standard Chemotherapy With and Without a PARP Inhibitor
A clinical trial compares standard chemotherapy with and without the addition of a PARP inihibitor, for patients whose pancreatic cancer is spreading again.
A clinical trial compares standard chemotherapy with and without the addition of a PARP inihibitor, for patients whose pancreatic cancer is spreading again.
A clinical trial compares FOLFIRINOX plus stereotactic body radiation therapy (SBRT) with just FOLFIRINOX for pancreatic cancer that has spread locally.
Researchers are looking at adding checkpoint drugs–a type of immunotherapy–to standard chemoradiation to shrink pancreatic cancer for surgery.
A clinical trial compares the effectiveness of low-dose continuous chemotherapy with and without high doses of vitamin C.
Richard Valdes has alternated standard pancreatic cancer treatments with clinical trials of immunotherapy and a pancreatic vaccine during his treatment.
A clinical trial for pancreatic cancer patients with the BRCA mutation tests the effectiveness of standard treatment plus a PARP inhibitor.
A chemoradiation clinical trial tests standard chemotherapy plus an anti-malaria drug and compares two types of radiation treatments, to slow tumor growth.
Researchers are testing a new combination of chemotherapies and radiation to shrink pancreatic cancer tumors and make surgical removal possible.
Rona Greenberg discusses the impact of BRCA2 on her family, and her search for the best clinical trial for her needs after her pancreatic cancer diagnosis.
A clinical trial compares two chemotherapy regimens to see which one is more effective at knocking out remaining cancer cells.